LISDEXAMFETAMINE


Synonyms	L-lysine-dextroamphetamine Lisdexamfetamine Lisdexamphetamine
Status
Molecule Category	Free-form
ATC	N06BA12
UNII	H645GUL8KJ
EPA CompTox	DTXSID00209652


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	VOBHXZCDAVEXEY-JSGCOSHPSA-N
Smiles	C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN
InChI	InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H25N3O
Molecular Weight	263.38
AlogP	1.19
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	8.0
Polar Surface Area	81.14
Molecular species	BASE
Aromatic Rings	1.0
Heavy Atoms	19.0

Cross References

Resources	Reference
ChEBI	135925
ChEMBL	CHEMBL1201222
DrugBank	DB01255
DrugCentral	4135
FDA SRS	H645GUL8KJ
Human Metabolome Database	HMDB0015385
Guide to Pharmacology	7213
PubChem	11597698
SureChEMBL	SCHEMBL158949
ZINC	ZINC000011680943

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).